Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jun;32(6):865–872. doi: 10.1128/aac.32.6.865

Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis.

N K Woolf 1, J W Ochi 1, E J Silva 1, P A Sharp 1, J P Harris 1, D D Richman 1
PMCID: PMC172297  PMID: 2843084

Abstract

The effectiveness of the antiviral agent ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) against guinea pig cytomegalovirus was tested in vitro in guinea pig embryonic fibroblasts and in vivo in an experimental guinea pig cytomegalovirus labyrinthitis model. In vitro, ganciclovir completely prevented guinea pig cytomegalovirus infection of guinea pig embryonic fibroblasts at concentrations above 32.6 micrograms/ml. In vivo, antibody-negative animals had an average 17-dB elevation in their auditory nerve compound action potential thresholds (P less than 0.01, t test) and showed signs bilaterally of guinea pig cytomegalovirus labyrinthitis 8 days after intrathecal inoculation of virus. Ganciclovir administration starting 1 day before inoculation prevented the development of both cochlear histopathologic change and hearing loss. Guinea pig cytomegalovirus meningitis was observed in both the drug-treated and untreated groups. High-pressure liquid chromatography confirmed the presence of ganciclovir in the serum, perilymph, and cerebrospinal fluid of the drug recipients. Prophylactic ganciclovir thus can protect the cochlea from the histopathologic changes and hearing loss normally associated with experimental guinea pig cytomegalovirus labyrinthitis.

Full text

PDF
865

Images in this article

868Image
on p.868
869Image
on p.869

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bach M. C., Bagwell S. P., Knapp N. P., Davis K. M., Hedstrom P. S. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Sep;103(3):381–382. doi: 10.7326/0003-4819-103-3-381. [DOI] [PubMed] [Google Scholar]
  2. Bia F. J., Griffith B. P., Fong C. K., Hsiung G. D. Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis. 1983 Mar-Apr;5(2):177–195. doi: 10.1093/clinids/5.2.177. [DOI] [PubMed] [Google Scholar]
  3. Cleveland P. H., Richman D. D., Oxman M. N., Wickham M. G., Binder P. S., Worthen D. M. Immobilization of viral antigens on filter paper for a [125I]staphylococcal protein A immunoassay: a rapid and sensitive technique for detection of herpes simplex virus antigens and antiviral antibodies. J Immunol Methods. 1979;29(4):369–386. doi: 10.1016/0022-1759(79)90008-5. [DOI] [PubMed] [Google Scholar]
  4. Davis L. E., Johnsson L. G., Kornfeld M. Cytomegalovirus labyrinthitis in an infant: morphological, virological, and immunofluorescent studies. J Neuropathol Exp Neurol. 1981 Jan;40(1):9–19. [PubMed] [Google Scholar]
  5. Felsenstein D., D'Amico D. J., Hirsch M. S., Neumeyer D. A., Cederberg D. M., de Miranda P., Schooley R. T. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med. 1985 Sep;103(3):377–380. doi: 10.7326/0003-4819-103-3-377. [DOI] [PubMed] [Google Scholar]
  6. Fong C. K., Cohen S. D., McCormick S., Hsiung G. D. Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Antiviral Res. 1987 Jan;7(1):11–23. doi: 10.1016/0166-3542(87)90035-0. [DOI] [PubMed] [Google Scholar]
  7. Hanshaw J. B., Dudgeon J. A. Congenital cytomegalovirus. Major Probl Clin Pediatr. 1978;17:97–152. [PubMed] [Google Scholar]
  8. Hanshaw J. B., Scheiner A. P., Moxley A. W., Gaev L., Abel V., Scheiner B. School failure and deafness after "silent" congenital cytomegalovirus infection. N Engl J Med. 1976 Aug 26;295(9):468–470. doi: 10.1056/NEJM197608262950902. [DOI] [PubMed] [Google Scholar]
  9. Harris J. P., Woolf N. K., Ryan A. F., Butler D. M., Richman D. D. Immunologic and electrophysiological response to cytomegaloviral inner ear infection in the guinea pig. J Infect Dis. 1984 Oct;150(4):523–530. doi: 10.1093/infdis/150.4.523. [DOI] [PubMed] [Google Scholar]
  10. Larke R. P., Wheatley E., Saigal S., Chernesky M. A. Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis. 1980 Nov;142(5):647–653. doi: 10.1093/infdis/142.5.647. [DOI] [PubMed] [Google Scholar]
  11. Laskin O. L., Cederberg D. M., Mills J., Eron L. J., Mildvan D., Spector S. A. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med. 1987 Aug;83(2):201–207. doi: 10.1016/0002-9343(87)90685-1. [DOI] [PubMed] [Google Scholar]
  12. Laskin O. L., Stahl-Bayliss C. M., Kalman C. M., Rosecan L. R. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis. 1987 Feb;155(2):323–327. doi: 10.1093/infdis/155.2.323. [DOI] [PubMed] [Google Scholar]
  13. Mar E. C., Cheng Y. C., Huang E. S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983 Oct;24(4):518–521. doi: 10.1128/aac.24.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Martin J. C., Dvorak C. A., Smee D. F., Matthews T. R., Verheyden J. P. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem. 1983 May;26(5):759–761. doi: 10.1021/jm00359a023. [DOI] [PubMed] [Google Scholar]
  15. Preece P. M., Pearl K. N., Peckham C. S. Congenital cytomegalovirus infection. Arch Dis Child. 1984 Dec;59(12):1120–1126. doi: 10.1136/adc.59.12.1120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Redfield D. C., Richman D. D., Oxman M. N., Kronenberg L. H. Psoralen inactivation of influenza and herpes simplex viruses and of virus-infected cells. Infect Immun. 1981 Jun;32(3):1216–1226. doi: 10.1128/iai.32.3.1216-1226.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Reichert C. M., O'Leary T. J., Levens D. L., Simrell C. R., Macher A. M. Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol. 1983 Sep;112(3):357–382. [PMC free article] [PubMed] [Google Scholar]
  18. Richman D. D., Cleveland P. H., Wopschall L. J. Immunoenzymatic staining of viral and chlamydial antigens in cell culture. Diagn Microbiol Infect Dis. 1985 Jul;3(4):353–358. doi: 10.1016/0732-8893(85)90010-0. [DOI] [PubMed] [Google Scholar]
  19. Rosecan L. R., Stahl-Bayliss C. M., Kalman C. M., Laskin O. L. Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine. Am J Ophthalmol. 1986 Apr 15;101(4):405–418. doi: 10.1016/0002-9394(86)90638-0. [DOI] [PubMed] [Google Scholar]
  20. Shanley J. D., Morningstar J., Jordan M. C. Inhibition of murine cytomegalovirus lung infection and interstitial pneumonitis by acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1985 Aug;28(2):172–175. doi: 10.1128/aac.28.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Smee D. F., Martin J. C., Verheyden J. P., Matthews T. R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983 May;23(5):676–682. doi: 10.1128/aac.23.5.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stagno S., Pass R. F., Dworsky M. E., Alford C. A., Jr Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol. 1982 Sep;25(3):563–576. doi: 10.1097/00003081-198209000-00014. [DOI] [PubMed] [Google Scholar]
  23. Stagno S., Reynolds D. W., Amos C. S., Dahle A. J., McCollister F. P., Mohindra I., Ermocilla R., Alford C. A. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics. 1977 May;59(5):669–678. [PubMed] [Google Scholar]
  24. Tenser R. B., Hsiung G. D. Comparison of guinea pig cytomegalovirus and guinea pig herpes-like virus: pathogenesis and persistence in experimentally infected animals. Infect Immun. 1976 Mar;13(3):934–940. doi: 10.1128/iai.13.3.934-940.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tocci M. J., Livelli T. J., Perry H. C., Crumpacker C. S., Field A. K. Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication. Antimicrob Agents Chemother. 1984 Feb;25(2):247–252. doi: 10.1128/aac.25.2.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Woolf N. K., Harris J. P., Ryan A. F., Butler D. M., Richman D. D. Hearing loss in experimental cytomegalovirus infection of the guinea pig inner ear: prevention by systemic immunity. Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):350–356. [PubMed] [Google Scholar]
  27. Woolf N. K., Ryan A. F. The development of auditory function in the cochlea of the mongolian gerbil. Hear Res. 1984 Mar;13(3):277–283. doi: 10.1016/0378-5955(84)90081-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES